Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
15.65
+0.60 (3.96%)
Jan 22, 2026, 1:08 PM EST - Market open
Seres Therapeutics Employees
Seres Therapeutics had 103 employees as of December 31, 2024. The number of employees decreased by 130 or -55.79% compared to the previous year.
Employees
103
Change (1Y)
-130
Growth (1Y)
-55.79%
Revenue / Employee
$3,408
Profits / Employee
$52,369
Market Cap
141.54M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103 | -130 | -55.79% |
| Dec 31, 2023 | 233 | -198 | -45.94% |
| Dec 31, 2022 | 431 | 98 | 29.43% |
| Dec 31, 2021 | 333 | 178 | 114.84% |
| Dec 31, 2020 | 155 | 47 | 43.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Fate Therapeutics | 181 |
| Sutro Biopharma | 178 |
| Caribou Biosciences | 147 |
| Connect Biopharma Holdings | 62 |
| Whitehawk Therapeutics | 40 |
| Spero Therapeutics | 32 |
| Elicio Therapeutics | 32 |
MCRB News
- 16 days ago - Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewsWire
- 2 months ago - Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 - GlobeNewsWire
- 3 months ago - Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 - GlobeNewsWire
- 3 months ago - Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - GlobeNewsWire
- 4 months ago - Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - GlobeNewsWire